The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2025 | 2L treatment for pancreatic cancer: limited data, clinical variables, future biomarkers
Juan Manuel O’Connor, MD, MSc, Instituto Alexander Fleming, Buenos Aires, Argentina, addresses the current challenges in second-line cancer treatment. Dr O’Connor notes limited robust data for second-line therapies, with existing clinical trials showing that chemotherapy activity depends on prior first-line treatment and patient factors like clinical condition and performance status. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2025 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think that there are no very good data in terms of the second line. There are some clinical trials that show the activity of the chemotherapy based on how it was the first line treatment for our patient, based on the clinical condition, performance status. So I think that the most of the important factors are clinical variables today. So we are looking for the future to the new biomarkers in order to determine what is the best candidate for a new treatment or new compound...
I think that there are no very good data in terms of the second line. There are some clinical trials that show the activity of the chemotherapy based on how it was the first line treatment for our patient, based on the clinical condition, performance status. So I think that the most of the important factors are clinical variables today. So we are looking for the future to the new biomarkers in order to determine what is the best candidate for a new treatment or new compound. But I think that it’s still a room for a clinical trial for a patient in second line treatment.
Read more...
